Welcome to the ATTD 2022 Interactive Program

The conference will officially run on Central European Summer Time (UTC+2) - Barcelona Time

To convert the conference times to your local time Click Here


 

Displaying One Session

Session Type
Plenary Session
Date
Thu, 28.04.2022
Session Time
08:10 - 08:55
Room
Hall 116

Is type 1 diabetes just one disease? Lessons in heterogeneity

Session Type
Plenary Session
Date
Thu, 28.04.2022
Session Time
08:10 - 08:55
Room
Hall 116
Lecture Time
08:10 - 08:30

Can we arrest type 1 diabetes?

Session Type
Plenary Session
Date
Thu, 28.04.2022
Session Time
08:10 - 08:55
Room
Hall 116
Lecture Time
08:30 - 08:50

Abstract

Abstract Body

After 100 years of insulin therapy, our insights in the pathogenesis of type 1 diabetes (T1D) have evolved and using the combination of genetic risk and presence of autoantibodies in the blood has allowed us to progress in the prediction of risk. Consortia worldwide are exploring the value of novel biomarkers and evaluate interventions targeting arresting progression of beta-cell destruction in people with newly diagnosed T1D or in those at risk of T1D. In Europe, the IMI2-funded projects INNODIA and INNODIA HARVEST focus on novel biomarker discovery and the consortium is executing 4 clinical trials in people with newly diagnosed T1D. An overview of activities, as well as the evolution of novel therapies for prevention and arrest of T1D will be discussed.

Hide

Q&A

Session Type
Plenary Session
Date
Thu, 28.04.2022
Session Time
08:10 - 08:55
Room
Hall 116
Lecture Time
08:50 - 08:55